Gene therapy brings light to rare eye disease in japanese patients

NCT ID NCT04516369

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a gene therapy called voretigene neparvovec in 4 Japanese patients with a rare inherited eye disease that causes vision loss. The treatment was given as an injection under the retina to replace the faulty gene. The goal was to see if it could safely improve light sensitivity and visual field.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIALLELIC RPE65 MUTATION-ASSOCIATED RETINAL DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    Meguro-ku, Tokyo, 152-8902, Japan